Dendrite Launches One-Source Sample Program For Comprehensive Product Promotion and Management.

Business Editors/Health/Medical Writers

MORRISTOWN, N.J.--(BUSINESS WIRE)--Aug. 18, 2003

Blends Market-Leading Software Applications And Interactive Marketing

Services With Best-In-Class Consulting And Professional Services From

BuzzeoPDMA, Inc.

Dendrite International, Inc. (NASDAQ: DRTE) today announced that it has launched its One-Source Sample(TM) program, the pharmaceutical industry's most comprehensive sample product promotion and management solution.

One-Source Sample serves the entire lifecycle of sample product promotion and blends market-leading software applications with best-in-class consulting and professional services. Helping to ensure PDMA (Prescription Drug Marketing Act) compliance, it combines Dendrite's interactive marketing services and sample management software solutions with the industry-leading compliance, auditing, consulting, and outsourcing services provided by BuzzeoPDMA, Inc.

The alliance between Dendrite and BuzzeoPDMA will enable both companies to achieve immediate market penetration. As of the launch, 37 of the top 50 pharmaceutical companies (including 19 of the top 20) are using elements of the One-Source Sample offering. Additionally, 18 of the top 50 utilize two or more components and nine companies use three or more components of the program, which consists of:

-- Sample Allocation, Accountability, Compliance, and Reporting

Software Applications: providing an automated foundation for

nearly all sample management-related business processes, this

suite of software applications is anchored by Dendrite's

market-leading Sample Guardian(TM) application

-- Sample Distribution and Fulfillment Services: consisting of

comprehensive interactive marketing services, including Single

Source Sampling(TM), a cooperative sample offer and

fulfillment service that provides samples to targeted

physicians across the United States 

-- Professional Services: consisting of inventory and

reconciliation, random and for-cause auditing, sales

representative closeouts, validation, data center operations,

production control, and training

-- Consulting Services: includes SOP generation, drug sample

program design, significant loss threshold development, and

compliance with government regulations

"The One-Source Sample offering will enable our pharmaceutical clients to receive a broader, richer range of sample promotion and management services from a single provider," said David Escalante, Dendrite Director of Global Solutions Marketing. "One-Source Sample customers can outsource their entire sample administration department or choose a particular professional or consulting service, or software application. Since all components are united together under one program, customers can evolve their use of our services over time, which gives them tremendous flexibility and scalability to meet their changing business needs."

Added Bill Buzzeo, Executive Vice President of BuzzeoPDMA, "One-Source Sample customers will quickly see the value and benefits of working with the two industry leaders in sample-based solutions. Before the launch, pharmaceutical companies had to piece together disjointed solutions from various providers, which ultimately costs more time, money, and resources to execute. One-Source Sample customers will now benefit from the single-provider approach that can satisfy all sample promotion and management requirements, help ensure compliance with government regulations, execute with a lower cost, and attain a higher level of success."

About Dendrite

Dendrite develops and delivers solutions that increase the productivity of sales, marketing, and clinical processes for pharmaceutical and other life science clients. For more information, visit www.dendrite.com.

About BuzzeoPDMA, Inc.

Founded over a decade ago, BuzzeoPDMA, Inc. is the recognized industry leader in assisting companies to comply with the policies and regulations of the Food and Drug Administration (FDA), Prescription Drug Marketing Act (PDMA), Drug Enforcement Administration (DEA), Controlled Substance Act (CSA), as well as state health care regulations and licensing. For more information, visit www.buzzeopdma.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including those which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for our products, our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on major customers; changes in demand for our products and services attributable to business and economic pressures on our major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; acquisitions; events that may affect the U.S. and world economies; retention of key senior managers; our ability to manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements.